Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127283
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2005-08-03
Brief Title:
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Randomised Double-Blind Placebo Controlled Multi-Centre Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII NovoSevenNiastase in Acute Intracerebral Haemorrhage
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST
Brief Summary:
This trial is conducted in Asia Europe Middle East North America Oceania and South America
The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa eptacog alfa activated in patients with acute intracerebral bleeding It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding
The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa eptacog alfa activated in patients with acute intracerebral bleeding It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-004202-24 | EUDRACT_NUMBER | None | None |